Cargando…

The Utility of SOX2 and AGR2 Biomarkers as Early Predictors of Tamoxifen Resistance in ER-Positive Breast Cancer Patients

BACKGROUND: Despite the undeniable benefit of tamoxifen therapy for ER-positive breast cancer patients, approximately one-third of those patients either do not respond to tamoxifen or develop resistance. Thus, it is a crucial step to identify novel, reliable, and easily detectable biomarkers indicat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zamzam, Yomna, Abdelmonem Zamzam, Yosra, Aboalsoud, Marwa, Harras, Heba
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460385/ https://www.ncbi.nlm.nih.gov/pubmed/34567804 http://dx.doi.org/10.1155/2021/9947540

Ejemplares similares

Could Obesity be a Triggering Factor for Endometrial Tubal Metaplasia to be a Precancerous Lesion?
por: El-Saka, Ayman M., et al.
Publicado: (2020)

AGR2 Predicts Tamoxifen Resistance in Postmenopausal Breast Cancer Patients
por: Hrstka, Roman, et al.
Publicado: (2013)

Genotypic Characterization of Carbapenem-Resistant Klebsiella pneumoniae Isolated from an Egyptian University Hospital
por: Taha, Marwa S., et al.
Publicado: (2023)

AGR2 and FOXA1 as prognostic markers in ER-positive breast cancer
por: Zhou, Meng, et al.
Publicado: (2023)

CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance
por: Gao, Tian, et al.
Publicado: (2014)

Sox2 promotes tamoxifen resistance in breast cancer cells
por: Piva, Marco, et al.
Publicado: (2014)

ER stress protein AGR2 precedes and is involved in the regulation of pancreatic cancer initiation
por: Dumartin, L, et al.
Publicado: (2017)

Diagnostic accuracy of SATB2 in identifying primary and metastatic colorectal carcinoma: a comparative immunohistochemical study
por: Elnady, Manar S, et al.
Publicado: (2022)

Integrative analysis of genomic and transcriptomic alterations of AGR2 and AGR3 in cancer
por: Fessart, Delphine, et al.
Publicado: (2022)

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen
por: Prat, A., et al.
Publicado: (2012)

Tamoxifen-independent Cre-activity in SMMHC-CreER(T2) mice
por: Steffensen, L.B., et al.
Publicado: (2022)

Disruption of the ER-α36-EGFR/HER2 Positive Regulatory Loops Restores Tamoxifen Sensitivity in Tamoxifen Resistance Breast Cancer Cells
por: Yin, Li, et al.
Publicado: (2014)

Checkpoint Kinase 2 Inhibition Can Reverse Tamoxifen Resistance in ER-Positive Breast Cancer
por: Tsoi, Ho, et al.
Publicado: (2022)

Targeting Oxidative Stress, Autophagy, and Apoptosis by Quercetin to Ameliorate Cisplatin-induced Peripheral Neuropathy in Rats
por: Mahmoud, Heba A., et al.
Publicado: (2023)

Tamoxifen Action in ER-Negative Breast Cancer
por: Manna, Subrata, et al.
Publicado: (2016)

Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα (+) breast cancer
por: Poulard, Coralie, et al.
Publicado: (2023)

The Effect of Omega-3 Supplements on Antioxidant Capacity in Patients with Type 2 Diabetes
por: Hajianfar, Hossein, et al.
Publicado: (2013)

Prevalence and Predictors of Potentially Inappropriate Medications Among Patients Aged ≥65 Years on Hospital Admissions in Kuwait
por: Alshammari, Hesah, et al.
Publicado: (2022)

Effects of ER-resident and secreted AGR2 on cell proliferation, migration, invasion, and survival in PANC-1 pancreatic cancer cells
por: Hong, Xian, et al.
Publicado: (2021)

FGFR2-Driven Signaling Counteracts Tamoxifen Effect on ERα-Positive Breast Cancer Cells
por: Turczyk, Lukasz, et al.
Publicado: (2017)

Hyperactivation of MAPK Induces Tamoxifen Resistance in SPRED2-Deficient ERα-Positive Breast Cancer
por: Vafeiadou, Vasiliki, et al.
Publicado: (2022)

AGR2 expression as a predictive biomarker for therapy response in esophageal squamous cell carcinoma
por: Lin, Chih-Hung, et al.
Publicado: (2022)

Secretion of pro-oncogenic AGR2 protein in cancer
por: Moidu, Nurshahirah Ashikin, et al.
Publicado: (2020)

The Clinical Utility of D-Dimer and Prothrombin Fragment (F1+2) for Peripheral Artery Disease: A Prospective Study
por: Arfan, Sara, et al.
Publicado: (2022)

SETD1A-SOX2 axis is involved in tamoxifen resistance in estrogen receptor α-positive breast cancer cells
por: Jin, Ming Li, et al.
Publicado: (2022)

An Overview of SARS-CoV-2 and Animal Infection
por: Mahdy, Mohamed A. A., et al.
Publicado: (2020)

Tamoxifen-Independent Recombination in the RIP-CreER Mouse
por: Liu, Yanmei, et al.
Publicado: (2010)

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
por: Esserman, Laura J, et al.
Publicado: (2005)

Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer
por: Liu, Ying, et al.
Publicado: (2020)

Effects of CreER(T2), 4-OH Tamoxifen, and Gender on CFU-F Assays
por: McHaffie, Sophie L., et al.
Publicado: (2016)

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
por: Menendez, Javier A., et al.
Publicado: (2021)

Limitations of Tamoxifen Application for In Vivo Genome Editing Using Cre/ER(T2) System
por: Ilchuk, Leonid A., et al.
Publicado: (2022)

Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization
por: Rittberg, Rebekah, et al.
Publicado: (2022)

The estrogen-regulated anterior gradient 2 (AGR2) protein in breast cancer: a potential drug target and biomarker
por: Salmans, Michael L, et al.
Publicado: (2013)

AGR2, an Endoplasmic Reticulum Protein, Is Secreted into the Gastrointestinal Mucus
por: Bergström, Joakim H., et al.
Publicado: (2014)

AGR2 is associated with gastric cancer progression and poor survival
por: ZHANG, JUN, et al.
Publicado: (2016)

Potential Role of AGR2 for Mammalian Skin Wound Healing
por: Kosykh, Anastasiya V., et al.
Publicado: (2023)

Targeting agr- and agr-Like Quorum Sensing Systems for Development of Common Therapeutics to Treat Multiple Gram-Positive Bacterial Infections
por: Gray, Brian, et al.
Publicado: (2013)

IGF‐1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER‐positive breast cancer
por: Kruger, Dinja T., et al.
Publicado: (2019)

FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression
por: Lv, Qing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v65nuvpf4f7m1sis3mafbaj5po